Blackpanther Shuri By Steve Paul Zillt

Important Notice: The International database is in BETA release. This means it is still under development and may contain inaccuracies. It is a substitute for the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to be appropriate or appropriate for you. Consult with your healthcare professional.

Always consult your healthcare provider to ensure the information provided.

Elderly patients. In elderly volunteers (over 75 years), when compared with young volunteers, differences in platelet aggregation and bleeding time were not revealed. Dose adjustment in elderly patients is not required.

- diuretics, beta-blockers, ACE inhibitors, BKK, lipid-lowering drugs, coronary vasodilators, hypoglycemic drugs (including insulin), antiepileptic drugs, drugs used in hormone replacement therapy, and glycoprotein IIb / IIIa inhibitors: not detected in clinically relevant clinical studies interactions.

SSRIs: affect platelet activation and increase risk of bleeding, therefore, caution should be exercised while using SSRIs and clopidogrel.

2. Grinshtein Yu.I., Savchenko EA, Filonenko IV, Grinshtein I.Yu., Savchenko A.A. Clopidogrel in patients with coronary artery atherosclerosis after coronary artery bypass grafting. Preliminary Results of an Open, Randomized, Comparative Study of Zeus // Cardiovascular Therapy and Prevention.- 2008.- 7 (6).

Excipients: anhydrous lactose - 108.125 mg, microcrystalline cellulose - 30 mg, pregelatinized starch - 12 mg, macrogol 6000 - 8 mg, hydrogenated castor oil - 4 mg.

After ingestion of 14 C-labeled clopidogrel, about 50% of the dose is excreted in the urine and approximately 46% with feces for 120 hours. T 1/2 of the main metabolite is 8 hours.

From the hemopoietic system: infrequently - thrombocytopenia, leukopenia, eosinophilia; rarely neutropenia, including severe neutropenia; very rarely - thrombotic thrombocytopenic purpura, aplastic anemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anemia.

Prevention of thrombotic complications in patients with myocardial infarction, ischemic stroke, or peripheral artery occlusion. In combination with acetylsalicylic acid for the prevention of thrombotic complications in acute coronary syndrome: with ST segment elevation with the possibility of thrombolytic therapy; without ST elevation segment (unstable angina, myocardial infarction without Q wave), including in patients undergoing stenting.

Pacienti s atriálnou fibriláciou Liek sa má podávať v jednej dennej dávke 75 mg. Kyselina acetylsalicylová (75-100 mg denne) its iniciovať a podávať v kombinácii s klopidogrelom.

Liek patrí do skupiny liekov nazıvaných antiagregačné lieky. Používa sa na predchádzanie vzniku krvných zrazenín (trombus) formujúczich sa v skôrnatených cievach, t.j. procesu známemu ako aterotrombóza, ktorý môže livesť k aterotrombotickým príhodám (ako sú náhla cievna mozgová príhoda, srdcový záchvat alebo smrť).

Pacienti s akútnym koronárnym syndrómom - Bez elevácie ST segmentu (nestabilná angína pektoris alebo non-Q infarkt myokardu): binds its musí začať jednou nasycovacou davolina 300 mg, potom its docovin 75 mg to 325 mg denne). Vzhľadom na to, že vyššie dávky ASA boli spojené s vyšším rizikom krvácania, odporúča sa, aby dávka ASA nebola vyššia ako 100 mg. - Akútny infarkt myokardu s eleváciou ST segmentu: liek musí podávať ako jedna denná dávka 75 mg, pričom liečba sa začína nasycovacou dávkou 300 mg v kombinácii s ASA a s trombolytikami alebo bez nich. U pacientov starších ako 75 rokov musí liečba klopidogrelom začať bez nasycovacej dávky. Kombinovaná liečba musí záčať čo najskôr po vzniku príznakov a musí pokračovať najmenej štyri týždne.

In acute coronary syndrome with ST segment elevation (acute myocardial infarction) with drug therapy and the possibility of thrombolytic therapy, Zilt ® is prescribed at a dose of 75 mg 1 time / day, starting with a loading dose, in combination with acetylsalicylic acid. combination with or without thrombolytics. For patients older than 75 years of age, treatment with Zilt® should be carried out without the use of a dose loading. Combination therapy is possible as soon as possible after the onset of symptoms and continues for at least 4 weeks. The effectiveness of combination therapy with clopidogrel and acetylsalicylic acid lasting more than 4 weeks in such patients has not been studied..

Ideal for dual antiplatelet therapy, especially in the postoperative period. In my practice, I often prescribe in combination with Cardiomagnyl in some cases after shunt reconstructive operations on the arteries of the lower extremities, as well as extracranial arteries.

When using clopidogrel in doses of 600 mg, the loading dose / 150 mg maintenance dose (600 mg / 150 mg) in patients with low metabolism, the exposure of the active metabolite was greater than 300 mg / 75 mg treatment regimen. In addition, the degree of inhibition of platelet aggregation was similar to that in groups of patients with high CYP2C19 isoenzyme that received clopidogrel according to the 300 mg / 75 mg regimen. However, the dosing regimen of clopidogrel in a group of patients with low activity of the CYP2C19 isoenzyme has not been determined in studies involving clinical outcomes. Clinical trials conducted by CYP2C19 isoenzyme activity.

C max of the active metabolite in blood plasma after loading a dose (300 mg) of clopidogrel is 2 times higher than that of a clopidogrel in a maintenance dose (75 mg / day). C max in blood plasma is reached approximately 30-60 minutes after taking the drug.

The standard dose of Zyllt is a compressa da 75 mg una volta al giorno, durante o lontano dai pasti. Nella sindrome coronarica acuta, Zyllt è usato assieme ad aspirina e trattamento generally comincia con a dose di carico di quattro compress da 75 mg. Tale dose of a standard dose of 75 mg of a standard dose of altimeter (nell'infarto miocardico con innalzamento del tratto ST) o fino a 12 mesi (in presenza di sindrome senza innalzamento del tratto ST).

It principio attivo di Zyllt, clopidogrel, is an inibitore dell'aggregazione piastrinica, ovverosia aiuta a prevenire the formazione di coaguli di sangue. The coagulazione of the blood avviene in seguito all'azione di speciali cell of the blood, the piastrine, che si aggregano (if attaccano una all'altra). Clopidogrel blocks the aggregation of the pest with a specific cholesterol ADP di legarsi has a specific recipe present sulla loro acreage. Ciò impedisce alle piastrine di diventare "collose", riducendo il rischio di formazione di coaguli del sangue e contribuendo a prevenire an altro attacco cardiaco o ictus.

Poiché Zyllt è a medicinal generico ed bioequivalente al medicinal di riferimento, si considera che beneficiary of the farmaco siano gli stessi del medicinale di riferimento.

The active substance in Zyllt, clopidogrel, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots are called platelets aggregating (sticking together). Clopidogrel stops the platelets aggregating by blocking a substance called ADP from a surface receptor. This stops the platelets becoming 'sticky', reducing the risk of a blood clot and helping to prevent another heart attack or stroke.

If you need more information about your medical condition or your treatment, read the leaflet package (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use medicine.

Blutungen können als Magenoder Darmblutungen auftreten sowie als blaue Flecken, Hämatome (ungewöhnliche Blutungen und Blutergüsse unter der Haut), Nasenbluten oder Blut im Urin. In wenigen Fällen sind Blutungen aus Gefäßen im Auge, im Inneren des Kopfes, in der Lunge or in Gelenken berichtet worden.

Wenn Sie eine Episode mit starkem Brustschmerz hatten (instabile Angina Pectoris oder Herzinfarkt), kann Ihnen Ihr Arzt 300 mg Zyllt (4 Tabletten mit 75 mg) einmal zu Behandlungsbeginn geben. Anschließend ist die übliche Dosis einmal täglich eine 75-mg-Tablet Zyllt, die täglich zur gleichen Zeit unabhängig von den Mahlzeiten eingenommen wird.

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use medicine.

patients who have had myocardial infarction (heart attack). Zyllt can be started between a few days and 35 days after the attack; patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). Zyllt can be started between seven days and six months after the stroke; patients with peripheral arterial disease (problems with blood flow in the arteries); patients who have a known 'acute coronary syndrome', when it should be given with aspirin, including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up) Zyllt can be used in patients who are having myocardial infarction with 'ST segment elevation' (an abnormal reading on the electrocardiogram or ECG) when the doctor thinks that they would benefit from treatment. It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or have had a non-Q-wave myocardial infarction..

Zyllt is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). Zyllt can be given to the following groups of patients: